UNSPSC 51102837: Ciprofloxacin/hydrocortisone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT250. This VA Drug Class (OT250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OTIC.

UNSPSC 51102837 Ciprofloxacin/hydrocortisone is a Commodity code that does not align with the recent state and local procurement activity tagged under it. The source contains four recent opportunities: two pharmaceutical procurement initiatives (generic multi-source drugs and direct-to-manufacturer prescriptions), one emergency medical supply solicitation, and one naloxone/drug deactivation systems bid. None of these directly concern ciprofloxacin/hydrocortisone—a topical antibiotic-corticosteroid combination typically used for ear infections. The misclassification appears systematic; the code appears to capture pharmaceutical contracting activity broadly rather than ciprofloxacin/hydrocortisone specifically.

The recent activity instead reflects state and local demand for emergency medical supplies, generic pharmaceuticals through cooperative purchasing vehicles, and specialty pharmacy initiatives. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, requiring NDC-coded products through three authorized wholesalers and a two-year contract term. Texas Health and Human Services Commission posted a Request for Information on direct-to-manufacturer prescriptions (response deadline April 3, 2026) to explore cost management through bypass of pharmacy benefit managers and group purchasing organizations. The City of Tampa issued an IFB for medical and first aid supplies (due March 13, 2026, estimated value $700,000) serving the Fire Department Rescue Division, with a 5 percent bid discount for certified Small Local Business Enterprises. Seminole County, Florida solicited naloxone and safe drug deactivation systems annually (due July 26, 2023, IFB number IFB60459723LAS) through quarterly deliveries, potentially FEMA-funded. Activity spans Minnesota, Texas, and Florida, driven by state health agencies, cooperative purchasing alliances, and county/city emergency services. The code shows little decision-relevant recent activity for ciprofloxacin/hydrocortisone procurement.